Kura Oncology vs Verastem
KURA and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KURA and VSTM compare
Kura Oncology and Verastem are about the same size, with market caps of $666M and $671M.
Verastem keeps more of each dollar of sales as profit, with a net margin of −232% compared with −369% at Kura Oncology.
Verastem scores higher on the StockData Score (3 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KURA | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $666M | $671M |
| Share price | $7.49 | $7.41 |
| Change, 1 year | −33.2% | −1.9% |
| Change, 5 years | −46.5% | −77.0% |
| Beta (5Y) | 2.30 | 2.66 |
| Employees | 260 | 102 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.4× | 7.7× (better) |
| P/B | 37.1× | 13.4× (better) |
| FCF yield | −13.4% | – |
| Growth | ||
| Revenue growth, 5Y average | – | −19.0% |
| Profitability | ||
| Operating margin | −394% | −183% (better) |
| Net margin | −369% | −232% (better) |
| FCF margin | −112% | – |
| Return on equity | −225% (better) | −471% |
| Financial health | ||
| Debt / equity | 0.55 | – |
| Interest coverage | −227.1× | −108.3× (better) |
| Current ratio | 3.60 (better) | 2.25 |
| Altman Z-score | −3.56 (better) | −7.37 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 98.0% | 109% |
| Held by insiders | 2.7% | 1.8% |
| Insider net buying, 12 months | $512K (better) | −$816K |
| Short interest, % of float | 14.6% | 22.1% |
Go deeper
- KURA stock overview
- KURA income statement
- KURA valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.